Researchers at University of Tsukuba have demonstrated that during Japan's COVID-19 booster vaccination campaign, online information influenced vaccination intentions in ways similar to the initial ...

This report provides useful evidence that EABR mRNA is at least as effective as standard S mRNA vaccines for the SARS-CoV-2 booster vaccine. Although the methodology and the experimental approaches ...

Valneva's Phase 2 data show strong, lasting immunity for its Pfizer-partnered Lyme vaccine as the company consolidates operations in France.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15. The results showed ...

Real-world effectiveness with the recommended single dose of respiratory syncytial virus (RSV) vaccination dipped in older ...

Whooping cough, a bacterial infection that can be especially dangerous for babies and young children, is on the rise. As of ...

By 2025, more than 13 billion doses of the vaccine are estimated to have been administered globally, saving untold millions ...

A joint procurement contract between the EU and Danish manufacturer Bavarian Nordic strengthens vaccine preparedness against ...

The FDA’s top vaccine regulator asserted in a staff email that the Covid vaccine caused at least 10 kids' deaths, but experts ...

Investing.com -- Valneva SE stock rises after the company reported final positive Phase II data for its Lyme disease vaccine candidate VLA15, showing strong immune responses following a third annual ...

Today’s announcement is a powerful example of what our Vaccine Alliance does best,” said An Vermeersch, Gavi’s Chief Vaccine ...

More than a year after its promised deadline to investors, drugmaker puts alarming results in federal government's "virtual ...